pa21
Showing 1 - 8 of 8
Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia Trial in Guangzhou (PA21, sevelamer carbonate)
Completed
- Chronic Kidney Disease Requiring Chronic Dialysis
- Hyperphosphatemia
- PA21
- sevelamer carbonate
-
Guangzhou, Guangdong, ChinaSouthern Medical University Nanfang Hospital
May 31, 2021
Hemodialysis Patients With Hyperphosphatemia Trial in Multiple Locations (PA21)
Completed
- Hemodialysis Patients With Hyperphosphatemia
- PA21
-
Multiple Locations, JapanJAPAN
Mar 2, 2018
Hemodialysis, Hyperphosphatemia Trial in Multiple Locations (PA21, Sevelamer HCl)
Completed
- Hemodialysis
- Hyperphosphatemia
- PA21
- Sevelamer hydrochloride
-
Multiple Locations, Japan(unnamed)
Mar 2, 2018
Hemodialysis, Hyperphosphatemia Trial in Multiple Locations (PA21)
Completed
- Hemodialysis
- Hyperphosphatemia
- PA21
-
Multiple Locations, Japan(unnamed)
Mar 2, 2018
Chronic Kidney Disease Requiring Hemodialysis Trial in Multiple Locations (PA21, Placebo)
Completed
- Chronic Kidney Disease Requiring Hemodialysis
- PA21
- Placebo
-
Multiple Locations, JapanJapan
Nov 27, 2017
Peritoneal Dialysis, Hyperphosphatemia Trial in Tokyo and Other Japanese City (PA21)
Completed
- Peritoneal Dialysis
- Hyperphosphatemia
- PA21
-
Tokyo and Other Japanese City, Japan(unnamed)
Nov 11, 2014
Drug Interaction Potentiation Trial in Lenexa (PA21, Warfarin)
Completed
- Drug Interaction Potentiation
- PA21
- Warfarin
-
Lenexa, KansasPRA International - Clinical Pharmacology Center
Feb 14, 2012
Drug Interaction Potentiation Trial in Anaheim (PA21, Digoxin)
Completed
- Drug Interaction Potentiation
- PA21
- Digoxin
-
Anaheim, CaliforniaACRI - Phase 1
Jan 17, 2012